New Two-Pronged attack tested for tough blood cancers
NCT ID NCT05583149
First seen Feb 01, 2026 · Last updated Apr 20, 2026 · Updated 13 times
Summary
This study is testing whether adding the drug acalabrutinib to a personalized cell therapy (liso-cel) is safe and effective for adults with aggressive B-cell lymphomas that have come back or not responded to other treatments. The main goal is to see how many participants achieve a complete disappearance of their cancer. This approach combines a pill that targets cancer cells with a one-time infusion of the patient's own modified immune cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth-Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.